Screener
Summit Therapeutics SMMT Compensation and benefits
Discontinued — last reported Q2 '23
Compensation and benefits at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Summit Therapeutics’s 10-Q, filed August 9, 2023.
- Filed
- Aug 9, 2023
- Fiscal quarter
- Q2 FY2023
- Calendar quarter
- Q2 2023
- Accession
- 0001599298-23-000077
| Line item | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 |
|---|---|---|
| Depreciation | 136 | 168 |
| Amortization of intangible assets | — | 480 |
| Gain on disposal of assets | (122) | — |
| Stock-based compensation | 4,650 | 6,492 |
| In-process research and development expense | 520,915 | — |
| Change in operating assets and liabilities: | ||
| Accounts receivable | 356 | 1,160 |
| Prepaid expenses | (4,565) | 1,231 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Summit Therapeutics's compensation and benefits?
- Summit Therapeutics (SMMT) reported compensation and benefits of $1.88M in Q2 2023.
- How has Summit Therapeutics's compensation and benefits changed year-over-year?
- Summit Therapeutics's compensation and benefits decreased by 24.9% year-over-year, from $2.5M to $1.88M.
- What does compensation and benefits mean?
- Total employee-related costs including salaries, wages, bonuses, commissions, stock-based compensation, health insurance, retirement contributions, and payroll taxes.
Ask your AI about Summit Therapeutics's compensation and benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude